Variant Creutzfeldt-Jakob disease: implications for the health care system

Area of Science:

• Neuroscience
• Infectious Diseases
• Public Health

Background:

• Variant Creutzfeldt-Jakob Disease (vCJD) emerged in 1996, identified as the human form of Bovine Spongiform Encephalopathy (BSE).
• Significant research investment has occurred globally, particularly in the UK, Europe, and the US, yet many aspects remain unknown.

Purpose of the Study:

• To review current knowledge on vCJD transmission routes and risks.
• To highlight challenges in diagnosis and treatment.
• To underscore the potential for iatrogenic and community spread.

Main Methods:

• Review of scientific literature and reported cases of vCJD.
• Analysis of vCJD characteristics, including infectivity and distribution.
• Examination of potential transmission vectors.

Main Results:

• vCJD infectivity is resistant to standard sterilization methods.
• Widespread distribution in the central nervous system and lymphoid system suggests transmission risk through surgical and ophthalmological procedures.
• Evidence indicates potential transmission via blood transfusion and tissue transplantation, with two likely cases reported in 2004.
• Long incubation periods with subclinical infection and infectivity are characteristic of vCJD.
• Under-diagnosis and misdiagnosis likely contribute to human-to-human transmission risks.

Conclusions:

• vCJD presents a persistent risk due to its resistance to decontamination and potential for transmission through medical interventions.
• The lack of ante-mortem screening tests and effective treatments complicates management and prevention.
• Further research and stringent public health measures are crucial to mitigate the spread of vCJD.